Drug intelligence / Profile preview

Zavetox

Development stage: Unknown
Lead developer: Mylin Biotech India
Modality: Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Zavetox** is Mylin Biotech's orally administered, acid- and bile-resistant enzobiotic capsule marketed for predialysis chronic kidney disease. This nutraceutical formulation combines synbiotics with proteolytic enzymes to improve intestinal protein digestion, limit delivery of undigested protein to the colon, and support a less proteolytic gut microbial environment. Its intended therapeutic effect is to reduce production of the protein-bound uremic toxins p-cresol sulfate and indoxyl sulfate, which are associated with chronic kidney disease progression. ([mylinbiotech.com](https://mylinbiotech.com/zavetox/))

Brand names: Zavetox
Other names: Enzobiotics

Targets

IS (Indoxyl sulfate)

Beyond the preview

Go deeper on Zavetox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zavetox.

Explore the full profile